140 related articles for article (PubMed ID: 24733135)
1. Investigation of pegloticase-associated adverse events from a nationwide reporting system database.
Gentry WM; Dotson MP; Williams BS; Hartley M; Stafford KR; Bottorff MB; Gandhi PK
Am J Health Syst Pharm; 2014 May; 71(9):722-7. PubMed ID: 24733135
[TBL] [Abstract][Full Text] [Related]
2. Infusion-related reactions with pegloticase, a recombinant uricase for the treatment of chronic gout refractory to conventional therapy.
Baraf HS; Yood RA; Ottery FD; Sundy JS; Becker MA
J Clin Rheumatol; 2014 Dec; 20(8):427-32. PubMed ID: 25417679
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular thromboembolic events associated with febuxostat: investigation of cases from the FDA adverse event reporting system database.
Gandhi PK; Gentry WM; Bottorff MB
Semin Arthritis Rheum; 2013 Jun; 42(6):562-6. PubMed ID: 23352248
[TBL] [Abstract][Full Text] [Related]
4. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study.
Sundy JS; Becker MA; Baraf HS; Barkhuizen A; Moreland LW; Huang W; Waltrip RW; Maroli AN; Horowitz Z;
Arthritis Rheum; 2008 Sep; 58(9):2882-91. PubMed ID: 18759308
[TBL] [Abstract][Full Text] [Related]
5. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.
Calabrese LH; Kavanaugh A; Yeo AE; Lipsky PE
Arthritis Res Ther; 2017 Aug; 19(1):191. PubMed ID: 28818095
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety of pegloticase in chronic gout refractory to conventional treatment.
Becker MA; Baraf HS; Yood RA; Dillon A; Vázquez-Mellado J; Ottery FD; Khanna D; Sundy JS
Ann Rheum Dis; 2013 Sep; 72(9):1469-74. PubMed ID: 23144450
[TBL] [Abstract][Full Text] [Related]
7. Pegloticase: a novel agent for treatment-refractory gout.
Shannon JA; Cole SW
Ann Pharmacother; 2012 Mar; 46(3):368-76. PubMed ID: 22395256
[TBL] [Abstract][Full Text] [Related]
8. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
[TBL] [Abstract][Full Text] [Related]
9. Pegloticase. An excessively dangerous and inadequately evaluated hypouricaemic drug.
Prescrire Int; 2014 Jul; 23(151):173-6. PubMed ID: 25162087
[TBL] [Abstract][Full Text] [Related]
10. Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study.
Chen SK; Liu J; Kim SC
BMJ Open; 2020 Dec; 10(12):e041167. PubMed ID: 33293318
[TBL] [Abstract][Full Text] [Related]
11. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database.
Gandhi PK; Gentry WM; Bottorff MB
Pharmacotherapy; 2012 Oct; 32(10):902-9. PubMed ID: 23033229
[TBL] [Abstract][Full Text] [Related]
12. Pegloticase: in treatment-refractory chronic gout.
Lyseng-Williamson KA
Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
[TBL] [Abstract][Full Text] [Related]
13. Pegloticase for treating refractory chronic gout.
George RL; Sundy JS
Drugs Today (Barc); 2012 Jul; 48(7):441-9. PubMed ID: 22844655
[TBL] [Abstract][Full Text] [Related]
14. Pegloticase hypersensitivity desensitisation: an outpatient, 3-bag, 12-step protocol.
Botson JK
BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32565437
[TBL] [Abstract][Full Text] [Related]
15. Pegloticase failure and a possible solution: Immunosuppression to prevent intolerance and inefficacy in patients with gout.
Berhanu AA; Krasnokutsky S; Keenan RT; Pillinger MH
Semin Arthritis Rheum; 2017 Jun; 46(6):754-758. PubMed ID: 27769591
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials.
Sundy JS; Baraf HS; Yood RA; Edwards NL; Gutierrez-Urena SR; Treadwell EL; Vázquez-Mellado J; White WB; Lipsky PE; Horowitz Z; Huang W; Maroli AN; Waltrip RW; Hamburger SA; Becker MA
JAMA; 2011 Aug; 306(7):711-20. PubMed ID: 21846852
[TBL] [Abstract][Full Text] [Related]
17. Pegloticase.
Schlesinger N; Yasothan U; Kirkpatrick P
Nat Rev Drug Discov; 2011 Jan; 10(1):17-8. PubMed ID: 21193861
[No Abstract] [Full Text] [Related]
18. Methaemoglobinaemia and haemolysis following pegloticase infusion for refractory gout in a patient with a falsely negative glucose-6-phosphate dehydrogenase deficiency result.
Geraldino-Pardilla L; Sung D; Xu JZ; Shirazi M; Hod EA; Francis RO
Rheumatology (Oxford); 2014 Dec; 53(12):2310-1. PubMed ID: 25224415
[No Abstract] [Full Text] [Related]
19. Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA's spontaneous reports database.
Szarfman A; Machado SG; O'Neill RT
Drug Saf; 2002; 25(6):381-92. PubMed ID: 12071774
[TBL] [Abstract][Full Text] [Related]
20. Hemolytic Anemia Induced by Pegloticase Infusion in a Patient With G6PD Deficiency.
Owens RE; Swanson H; Twilla JD
J Clin Rheumatol; 2016 Mar; 22(2):97-8. PubMed ID: 26906307
[No Abstract] [Full Text] [Related]
[Next] [New Search]
